

SMITH L S  
Form SC 13D/A  
June 03, 2010

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D/A  
(Amendment No. 14)

INFORMATION TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT  
TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO  
§240.13D-2(a)

DGSE COMPANIES, INC.  
(Name of Issuer)

Common Stock, par value \$0.01 per share  
(Title of Class of Securities)

23323G106  
(CUSIP Number)

Dr. L.S. Smith  
519 I 30, Suite 243  
Rockwall, Texas  
Telephone No.: (972) 772-3091  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

June 3, 2010  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D/A, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that Section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 23323G106

SCHEDULE 13D/A

1 NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Dr. L.S. Smith

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

N/A

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7 SOLE VOTING POWER 6,404,914 (including 945,634 shares underlying exercisable options)* 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 2,847,938 (including 945,634 shares underlying exercisable options)* 10 SHARED DISPOSITIVE POWER 0
--	---

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,847,938 (including 945,634 shares underlying exercisable options)\*

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

25.3% (see Item 5)

14 TYPE OF REPORTING PERSON

IN

\* Pursuant to the proxies described herein, Dr. Smith may be considered a member of a “group” with the persons granting those proxies (collectively, the “Grantors” and each, a “Grantor”) for purposes of this Schedule 13D/A. Dr. Smith expressly disclaims beneficial ownership of the 3,556,976 shares of common stock of the issuer held by the Grantors, and expressly disclaims membership in any group with any Grantor. All options held by Dr. Smith are exercisable within 60 days.



Item 1. Security and Issuer.

This statement relates to the common stock, par value \$0.01 per share (the "Common Stock"), of DGSE Companies, Inc., a Nevada corporation (the "Issuer"), whose principal executive office is located at 11311 Reeder Road, Dallas, Texas 75229.

Item 2. Identity and Background.

(a) Dr. L.S. Smith.

(b) 519 Interstate 30, Suite 243, Rockwall, Texas 75087.

(c) Dr. Smith is Chairman of the Board of Directors and Chief Executive Officer of the Issuer, the principal executive office of which is located at the address named in Item 1 of this Schedule 13D/A.

(d) During the last five years, Dr. Smith has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) Dr. Smith has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in or was subject to (i) a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws; or (ii) a finding of any violation with respect to such laws.

(f) Dr. Smith is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration.

Dr. Smith was given irrevocable proxy power over 3,000,000 shares (the "NTR Proxy") of the common stock of the Issuer, par value \$0.01 per share (the "Common Stock"), held by NTR Metals, LLC, a Texas limited liability company ("NTR") for a period of four (4) years, beginning May 25, 2010 (the "Closing Date"), in return for his grant to NTR of an option (the "Option") to acquire one million (1,000,000) shares of the Common Stock owned by Dr. Smith (the "Stock Option Shares"). Dr. Smith was given irrevocable proxy power over 310,000 shares (the "Alan-Lee Proxy") of Common Stock owned by Mr. Craig Alan-Lee, a director of the Issuer ("Mr. Alan-Lee"), for a period of four (4) years, dated May 18, 2010 and effective as of the Closing Date, in return for no consideration. Additionally, Dr. Smith was given irrevocable proxy power over 246,976 shares (the "Oyster Proxy") of Common Stock owned by Mr. William H. Oyster, an officer and director of the Issuer ("Mr. Oyster"), for a period of four (4) years, dated May 18, 2010 and effective as of the Closing Date, in return for no consideration.

---

Item 4. Purpose of Transaction.

The NTR Proxy, the Alan-Lee Proxy, and the Oyster Proxy (collectively, the "Proxies") were obtained for, and are being held for, the purpose of maintaining Dr. Smith's voting control over a majority of the Common Stock of the Issuer. The Proxies were obtained in connection with the transfer of 3,376,361 shares of Common Stock from Stanford International Bank, Ltd., an entity organized under the laws of Antigua, to NTR and 37 individuals including Msrs. Oyster and Alan-Lee.

Other than the Proxies, the Option, and the Smith Irrevocable Proxy Agreement, each as discussed herein, Dr. Smith does not have any plans or proposals which relate to or would result in (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present board of directors or management of the Company; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) changes causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above. However, Dr. Smith reserves the right to propose or undertake or participate in any of the foregoing actions in the future.

Item 5. Interest in Securities of Issuer.

(a) As of the date of this report, Dr. Smith beneficially owns 6,404,914 shares (including 945,634 shares underlying exercisable options) of the Issuer's Common Stock, which in the aggregate, represents 57% of the currently outstanding shares of the Issuer's Common Stock (for purposes of calculating the percentage, the 945,634 shares subject to Dr. Smith's exercisable options were assumed to be outstanding). Dr. Smith disclaims beneficial ownership of 3,556,976 of those shares which Dr. Smith has the power to vote pursuant to the Proxies granted by the owners thereof to Dr. Smith, and this report should not be deemed to be an admission that Dr. Smith is the beneficial owner of such shares of Common Stock. Dr. Smith further disclaims membership in any group with the persons granting him the Proxies with respect to those 3,557,276 shares of Common Stock.

The foregoing calculations of percentage ownership are based on 10,290,252 shares of Common Stock outstanding, as reported by the Issuer's transfer agent on June 2, 2010.

(b) Dr. Smith has sole voting and dispositive power with respect to 2,847,938 shares of the Issuer's Common Stock (including 945,634 shares underlying exercisable options) and sole voting power and no dispositive power with respect to 3,557,276 shares subject to the Proxies.

Dr. Smith disclaims beneficial ownership of the 3,557,276 shares subject to the Proxies.

(c) Not applicable.

(d) Dr. Smith confirms that, except as described herein, he is not aware of any other person with the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any of the shares of common stock of the Issuer beneficially owned by him.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

NTR granted the NTR Proxy to Dr. Smith in return for the Option, as represented by that certain Irrevocable Proxy to Vote Shares, dated May 25, 2010, by and between NTR and Dr. Smith, a copy of which is attached hereto as Exhibit 99.1. The Option, as represented by that certain Option Contract, dated May 25, 2010, by and between NTR and Dr. Smith, a copy of which is attached hereto as Exhibit 99.2, provides that NTR may acquire the Stock Option Shares at an exercise price of \$6.00 per share and the release of Dr. Smith's personal guaranty of the Issuer's \$1,500,000 line of credit with Texas Capital Bank, N.A. for the first two (2) years following the Closing Date. The Option Contract further provides that if the Option remains unexercised on the second anniversary following the Closing Date, then the exercise price shall increase to \$10.00 per share and the release of Dr. Smith's guaranty of the Issuer's \$1,500,000 line of credit with Texas Capital Bank, N.A. for the third and fourth years following the Closing Date. The NTR Proxy will terminate upon the earlier of (a) NTR's exercise of the Option, (b) Dr. Smith's death or the appointment of a legal guardian for Dr. Smith due to incapacity by reason of physical or mental condition, or (c) the fourth anniversary of the Closing Date.

Pursuant to that certain Smith Irrevocable Proxy Agreement, dated May 25, 2010, by and between Dr. Smith and NTR, a copy of which is attached hereto as Exhibit 99.3, Dr. Smith agreed to appoint NTR as Dr. Smith's irrevocable proxy to vote his Common Stock with respect to any matter regarding the Issuer on which Dr. Smith may be entitled to vote upon the earlier of (a) NTR's exercise of the Option or (b) Dr. Smith's death or the appointment of a legal guardian for Dr. Smith due to incapacity by reason of physical or mental condition. If and when executed, the term of this proxy will be for the remainder of the four (4) year period following the Closing Date.

Mr. Alan-Lee granted the Alan-Lee Proxy to Dr. Smith for a period of four (4) years, dated May 18, 2010 and effective as of the Closing Date, in return for no consideration, as represented by that certain Irrevocable Proxy to Vote Shares, dated May 18, 2010 and effective as of the Closing Date, by and between Mr. Oyster and Dr. Smith, a copy of which is attached hereto as Exhibit 99.4. Mr. Oyster granted the Oyster Proxy to Dr. Smith for a period of four (4) years, dated May 18, 2010 and effective as of the Closing Date, in return for no consideration, as represented by that certain Irrevocable Proxy to Vote Shares, dated May 18, 2010 and effective as of the Closing Date, by and between Mr. Oyster and Dr. Smith, a copy of which is attached hereto as Exhibit 99.5. Additionally, the information set forth, or incorporated by reference, in Items 3 through 5 of this Statement is hereby incorporated by reference in this Item 6.

Item 7. Materials to be Filed as Exhibits.

99.1 Irrevocable Proxy to Vote Shares, dated May 25, 2010, by and between NTR Metals, LLC and Dr. L.S. Smith.

99.2 Option Contract, dated May 25, 2010, by and between NTR Metals, LLC and Dr. L.S. Smith.

99.3 Smith Irrevocable Proxy Agreement, dated May 25, 2010, by and between NTR Metals, LLC and Dr. L.S. Smith.

99.4 Irrevocable Proxy to Vote Shares, dated May 18, 2010, by and between Mr. William H. Oyster and Dr. L.S. Smith.

99.5 Irrevocable Proxy to Vote Shares, dated May 18, 2010, by and between Mr. Craig Alan-Lee and Dr. L.S. Smith.

---

EXHIBITS

Exhibit No.	Description
99.1	Irrevocable Proxy to Vote Shares, dated May 25, 2010
99.2	Option Contract, dated May 25, 2010
99.3	Smith Irrevocable Proxy Agreement, dated May 25, 2010
99.4	Irrevocable Proxy to Vote Shares, dated May 18, 2010
99.5	Irrevocable Proxy to Vote Shares, dated May 18, 2010

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 3, 2010

(Date)

/s/ Dr. L.S. Smith

(Signature)

Dr. L.S. Smith

(Name and Title)

---